Prolium Bioscience

News

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.